Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Development of oral anticoagulants.

× No keyword cloud information.

16 in total

Review 1. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors: Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal: Circulation Date: 2003-04-01 Impact factor: 29.690

Review 2. New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Authors: Shannon M Bates; Jeffrey I Weitz
Journal: Br J Pharmacol Date: 2005-04 Impact factor: 8.739

3. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.

Authors: Joachim Stangier; Bengt I Eriksson; Ola E Dahl; Lennart Ahnfelt; Gerhard Nehmiz; Hildegard Stähle; Karin Rathgen; Robbyna Svärd
Journal: J Clin Pharmacol Date: 2005-05 Impact factor: 3.126

4. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.

Authors: Dagmar Kubitza; Michael Becka; Barbara Voith; Michael Zuehlsdorf; Georg Wensing
Journal: Clin Pharmacol Ther Date: 2005-10 Impact factor: 6.875

5. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

Authors: B I Eriksson; O E Dahl; H R Büller; R Hettiarachchi; N Rosencher; M-L Bravo; L Ahnfelt; F Piovella; J Stangier; P Kälebo; P Reilly
Journal: J Thromb Haemost Date: 2005-01 Impact factor: 5.824

Review 6. New anticoagulants.

Authors: J I Weitz; S M Bates
Journal: J Thromb Haemost Date: 2005-08 Impact factor: 5.824

7. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

Authors: B I Eriksson; O E Dahl; L Ahnfelt; P Kälebo; J Stangier; G Nehmiz; K Hermansson; V Kohlbrenner
Journal: J Thromb Haemost Date: 2004-09 Impact factor: 5.824

Review 8. A novel approach to thrombin inhibition.

Authors: Jeffrey I Weitz
Journal: Thromb Res Date: 2003-07-15 Impact factor: 3.944

9. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

Authors: Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dietmar Gansser; Willy Roth
Journal: Br J Clin Pharmacol Date: 2007-05-15 Impact factor: 4.335

10. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Authors: Charles W Francis; Scott D Berkowitz; Philip C Comp; Jay R Lieberman; Jeffrey S Ginsberg; Guy Paiement; Gary R Peters; Anne W Roth; Jennifer McElhattan; Clifford W Colwell
Journal: N Engl J Med Date: 2003-10-30 Impact factor: 91.245

1 in total

Review 1. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors: Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal: J Thorac Cardiovasc Surg Date: 2014-06-30 Impact factor: 5.209

1 in total